Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP

Eur J Pharmacol. 1985 Oct 8;116(1-2):179-81. doi: 10.1016/0014-2999(85)90201-8.

Abstract

Combined administration of nomifensine, a DA reuptake inhibitor, and MPTP completely prevented the long-term (30 days post-treatment) striatal DA depletions induced by MPTP in mice. Cotreatment with desipramine and clomipramine or fluoxetine, inhibitors of NE and 5-HT, respectively had no effect on DA neurotoxicity of MPTP. The findings indicate that MPTP (or MPP+) is a substrate for the specific DA reuptake system and may explain, in part, its selective toxic effects on DA neurons.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Clomipramine / pharmacology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Desipramine / pharmacology
  • Dopamine / metabolism*
  • Fluoxetine / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nomifensine / pharmacology
  • Norepinephrine / metabolism*
  • Pyridines / antagonists & inhibitors
  • Pyridines / toxicity*
  • Serotonin Antagonists / pharmacology*

Substances

  • Pyridines
  • Serotonin Antagonists
  • Fluoxetine
  • Nomifensine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Clomipramine
  • Desipramine
  • Dopamine
  • Norepinephrine